Rhythm Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2026 was MXN7,976 Mil.
During the past 12 months, Rhythm Pharmaceuticals's average Total Assets Growth Rate was 40.90% per year.
During the past 3 years, the average Total Assets Growth Rate was 22.90% per year.
During the past 5 years, the average Total Assets Growth Rate was 39.30% per year.
During the past 10 years, the average Total Assets Growth Rate was 51.30% per year.
During the past 11 years, Rhythm Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 107.30%. The lowest was 22.90%. And the median was 53.85%.
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Rhythm Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Rhythm Pharmaceuticals Total Assets Related Terms
Rhythm Pharmaceuticals Total Assets Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Rhythm Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rhythm Pharmaceuticals (MEX:RYTM) has a Total Assets of MXN7,976 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Rhythm Pharmaceuticals and its competitors.
Is Rhythm Pharmaceuticals' Total Assets too high?
Rhythm Pharmaceuticals' current Total Assets is MXN7,976 Mil. Overall, Rhythm Pharmaceuticals has a GF Score™ of 56/100, reflecting its overall financial health beyond just this single metric.
How does Rhythm Pharmaceuticals' Total Assets compare to MIRM and SYRE?
Rhythm Pharmaceuticals' Total Assets of MXN7,976 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Rhythm Pharmaceuticals and its competitors. Rhythm Pharmaceuticals's current Total Assets is MXN7,976 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhythm Pharmaceuticals stock overvalued right now?
Rhythm Pharmaceuticals (MEX:RYTM) has a current Total Assets of MXN7,976 Mil. The stock's GF Value™ is MXN1,874.87, compared to a current price of MXN1,866.76 — trading 0.4% below its estimated fair value. The current Total Assets is MXN7,976 Mil. Rhythm Pharmaceuticals' overall GF Score™ is 56/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Rhythm Pharmaceuticals (MEX:RYTM), the current Total Assets is MXN7,976 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rhythm Pharmaceuticals (MEX:RYTM) Overvalued in 2026?
Based on GuruFocus' analysis, Rhythm Pharmaceuticals stock appears to be undervalued.
The current stock price of MXN1,866.76 is trading 0.4% below its estimated GF Value™ of MXN1,874.87.
Key valuation signals for MEX:RYTM:
Total Assets: MXN7,976 Mil
GF Value™: MXN1,874.87 vs. price of MXN1,866.76 (0.4% below fair value)
No single metric tells the full story. See the MEX:RYTM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
56GF Score
Get the complete analysis for MEX:RYTM
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:RYTM has been successfully added to your 
